S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
The “Perfect Storm” for Gold (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
The #1 Crypto for 2024 (Ad)
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Bear Market Funds to Watch This Year
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
The “Perfect Storm” for Gold (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
The #1 Crypto for 2024 (Ad)
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Bear Market Funds to Watch This Year
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
The “Perfect Storm” for Gold (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
The #1 Crypto for 2024 (Ad)
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Bear Market Funds to Watch This Year
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
The “Perfect Storm” for Gold (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
The #1 Crypto for 2024 (Ad)
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Bear Market Funds to Watch This Year
Free Trial

Kiniksa Pharmaceuticals (KNSA) Earnings Date, Estimates & Call Transcripts

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free knsa Stock Alerts
$16.88
-0.07 (-0.41%)
(As of 04/18/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Apr. 23
Before Market Opens
Confirmed
Actual EPS
(Feb. 28)
$0.04 Beat By $0.15
Consensus EPS
(Feb. 28)
-$0.11
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

KNSA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KNSA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Kiniksa Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.13)($0.13)($0.13)
Q2 20241($0.16)($0.16)($0.16)
Q3 20241($0.18)($0.18)($0.18)
Q4 20241($0.20)($0.20)($0.20)
FY 20244($0.67)($0.67)($0.67)
Q1 20251($0.19)($0.19)($0.19)
Q2 20251($0.18)($0.18)($0.18)
Q3 20251($0.15)($0.15)($0.15)
Q4 20251($0.12)($0.12)($0.12)
FY 20254($0.64)($0.64)($0.64)

KNSA Earnings Date and Information

Kiniksa Pharmaceuticals last released its earnings results on February 28th, 2024. The reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.15. The company had revenue of $83.40 million for the quarter, compared to analysts' expectations of $72.31 million. Kiniksa Pharmaceuticals has generated $0.18 earnings per share over the last year ($0.18 diluted earnings per share) and currently has a price-to-earnings ratio of 93.8. Earnings for Kiniksa Pharmaceuticals are expected to decrease in the coming year, from ($0.06) to ($0.44) per share. Kiniksa Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Tuesday, April 23rd, 2024. Kiniksa Pharmaceuticals will be holding an earnings conference call on Tuesday, April 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call..

Kiniksa Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
4/23/2024
Confirmed)		-------  
2/28/2024Q4 2023($0.11)$0.04+$0.15($0.27)$72.31 million$83.40 million
10/31/2023Q3 2023($0.18)($0.20)($0.02)($0.20)$62.53 million$67.05 million
7/25/2023Q2 2023($0.16)($0.02)+$0.14($0.25)$52.33 million$71.47 million
5/2/2023Q1 2023($0.18)($0.18)-($0.18)$45.95 million$48.35 million
2/28/2023Q4 2022($0.24)$0.06+$0.30$0.06$47.18 million$61.88 million
11/1/2022Q3 2022$0.38$0.67+$0.29($1.84)$113.00 million$99.14 million
8/3/2022Q2 2022($0.43)($0.29)+$0.14($0.29)$27.68 million$26.97 million
5/3/2022Q1 2022($0.52)($0.36)+$0.16($0.36)$31.93 million$32.19 million    
2/22/2022Q4 2021($0.44)($0.53)($0.09)($0.53)$16.32 million$18.75 million    
11/1/2021Q3 2021($0.65)($0.44)+$0.21($0.44)$9.92 million$12.10 million    
8/3/2021Q2 2021($0.69)($0.61)+$0.08($0.61)$2.56 million$7.70 million    
5/4/2021Q1 2021($0.73)($0.72)+$0.01($0.72)--

Kiniksa Pharmaceuticals Earnings - Frequently Asked Questions

When is Kiniksa Pharmaceuticals's earnings date?

Kiniksa Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Tuesday, April 23rd, 2024. Learn more on KNSA's earnings history.

Did Kiniksa Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported $0.04 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.11) by $0.15. Learn more on analysts' earnings estimate vs. KNSA's actual earnings.

How much revenue does Kiniksa Pharmaceuticals generate each year?

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a recorded annual revenue of $270.26 million.

How much profit does Kiniksa Pharmaceuticals generate each year?

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a recorded net income of $14.08 million. KNSA has generated $0.18 earnings per share over the last four quarters.

What is Kiniksa Pharmaceuticals's price-to-earnings ratio?

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a trailing price-to-earnings ratio of 93.78.

What is Kiniksa Pharmaceuticals's EPS forecast for next year?

Kiniksa Pharmaceuticals's earnings are expected to decrease from ($0.06) per share to ($0.44) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:KNSA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The “Perfect Storm” for Gold
Gold Safe Exchange
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company